Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: implications for Parkinson's disease.
Parkinson's disease is associated with degeneration of dopaminergic cell bodies in the substantia nigra. It has been suggested that salsolinol, an endogenous metabolite of dopamine, may be involved in this process. An inverse relationship between Parkinson's disease and smoking (nicotine intake) has been observed in epidemiological studies. Moreover, neuroprotective effects of nicotine in various experimental models have been observed. In this study we sought to determine whether salsolinol-induced cytotoxicity in SH-SY5Y human neuroblastoma cells, a cloned cell line which expresses dopaminergic activity, could also be prevented by nicotine pretreatment, and if so, which nicotinic receptors may mediate the actions of nicotine. Exposure of SH-SY5Y cells to 0.8 mM salsolinol for 24 hours resulted in approximately 80% cell death as determined by 3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Pretreatment of cells with 0.1 mM nicotine resulted in inhibition of salsolinol-induced cytotoxicity. The effects of nicotine were blocked by mecamylamine, a non-selective nicotinic antagonist as well as conotoxins with selective antagonism against alpha3-containing nicotinic receptor subunits. The effects of nicotine were not affected by dihydro-beta-erythroidine or methyllycaconitine, selective antagonists against alpha4-beta2 or alpha7 nicotinic receptors, respectively. It is suggested that selective nicotinic agonists may be of therapeutic potential in at least a subpopulation of Parkinsonian patients.
Copeland
Robert L
RL
Department of Pharmacology and Department of Microbiology, College of Medicine, Howard University, Washington, DC 20059, USA.
Leggett
Yaminah A
YA
Kanaan
Yasmine M
YM
Taylor
Robert E
RE
Tizabi
Yousef
Y
D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D020916:Conotoxins / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D007546:Isoquinolines / Q000037:antagonists & inhibitors* / Q000633:toxicity; D009447:Neuroblastoma; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009498:Neurotoxins / Q000633:toxicity*; D009538:Nicotine / Q000494:pharmacology*; D013778:Tetrazolium Salts; D013844:Thiazoles
D020916:Conotoxins; D007546:Isoquinolines; D018696:Neuroprotective Agents; D009498:Neurotoxins; D013778:Tetrazolium Salts; D013844:Thiazoles; D009538:Nicotine; C036617:salsolinol; C022616:thiazolyl blue